Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China

BACKGROUND: FG-4592 (roxadustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) promoting coordinated erythropoiesis through the transcription factor HIF. Two Phase 2 studies were conducted in China to explore the safety and efficacy of FG-4592 (USAN name: roxadusta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nephrol Dial Transplant
Main Authors: Chen, Nan, Qian, Jiaqi, Chen, Jianghua, Yu, Xueqing, Mei, Changlin, Hao, Chuanming, Jiang, Gengru, Lin, Hongli, Zhang, Xinzhou, Zuo, Li, He, Qiang, Fu, Ping, Li, Xuemei, Ni, Dalvin, Hemmerich, Stefan, Liu, Cameron, Szczech, Lynda, Besarab, Anatole, Neff, Thomas B., Peony Yu, Kin-Hung, Valone, Frank H.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837707/
https://ncbi.nlm.nih.gov/pubmed/28371815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfx011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados